BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Joncia regulatory update

Pierre Fabre said Australia's Therapeutic Goods Administration ( TGA) approved Joncia milnacipran to treat fibromyalgia. Milnacipran is a norepinephrine and serotonin reuptake inhibitor (NSRI). Johnson...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >